IL-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8+ T cells resulting in a failure to lyse tumor cells

Human myeloid dendritic cells transduced with an adenoviral interleukin-10 gene construct inhibit human skin graft rejection in humanized NOD-scid chimeric mice

“…Whilst the ability of IL-10 transduced DC to produce CTL was not assessed in this study, other studies have found that IL-10 is capable of inhibiting DC production of CTL to specific antigens. 41 It is therefore possible that one of the mechanisms of allograft protection seen in these experiments is an IL-10-mediated reduction in the donor-specific CTL response. As DC transduced with AdV IL-10 are capable of secretion of IL-10 ( Table 2) it is also possible that this paracrine secretion of IL-10 had an immunosuppressive effect upon Langerhans cells or DC resident within the skin grafts modifying their allostimulatory behaviour.…”

Dendritic cell density and activation status in human breast cancer – CD1a, CMRF-44, CMRF-56 and CD-83 expression

“…This is a possible mechanism of induction of tumour tolerance (Steinbrink et al, 1999). Alternatively, mature DC may migrate or apoptose and be effectively lost from the primary tumour microenvironment (Esche et al, 1999;Pirtskhalaishvili et al, 2000).…”

Generation of dendritic cell-based vaccines for cancer therapy

“…Immature DC -obtained after 7 days of culture with GM -CSF and IL-4 -can be grown to mature DC by coculturing with TNF-a, IL-6, IL-1b, and PGE2 or, alternatively, with a so-called monocyte conditioned medium (MCM) for another 3 days (maturation phase) (Thurner et al, 1999b). In contrast to immature DC, mature DC are much more potent in inducing T H 1 and CTL responses in vitro and are resistant to immunosuppressive effects of tumour-derived IL-10 (Steinbrink et al, 1999). Therefore, mature DC have been used in recent vaccination protocols (Thurner et al, 1999a).…”